How to treat severe Acinetobacter baumannii infections.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
7
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
ppublish
Résumé
To update the management of severe Acinetobacter baumannii infections (ABI), particularly those caused by multi-resistant isolates. The in vitro activity of the various antimicrobial agents potentially helpful in treating ABI is highly variable and has progressively decreased for many of them, limiting current therapeutic options. The combination of more than one drug is still advisable in most circumstances. Ideally, two active first-line drugs should be used. Alternatively, a first-line and a second-line drug and, if this is not possible, two or more second-line drugs in combination. The emergence of new agents such as Cefiderocol, the combination of Sulbactam and Durlobactam, and the new Tetracyclines offer therapeutic options that need to be supported by clinical evidence. The apparent limitations in treating infections caused by this bacterium, the rapid development of resistance, and the serious underlying situation in most cases invite the search for alternatives to antibiotic treatment, the most promising of which seems to be bacteriophage therapy.
Identifiants
pubmed: 37930071
doi: 10.1097/QCO.0000000000000974
pii: 00001432-202312000-00021
doi:
Substances chimiques
Anti-Bacterial Agents
0
Sulbactam
S4TF6I2330
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
596-608Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 2016; 37:1288–1301.
Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101–106.
Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii . J Clin Microbiol 2000; 38:4086–4095.
Tacconelli E, Cataldo MA, De Pascale G, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother 2008; 62:1130–1137.
Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis 2010; 42:741–746.
Vitkauskiene A, Dambrauskiene A, Cerniauskiene K, et al. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection. Scand J Infect Dis 2013; 45:213–218.
Garnacho-Montero J, Gutiérrez-Pizarraya A, Díaz-Martín A, et al. Acinetobacter baumannii in critically ill patients: molecular epidemiology, clinical features and predictors of mortality. Enferm Infect Microbiol Clin 2016; 34:551–558.
Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649–655.
Ju M, Hou D, Chen S, et al. Risk factors for mortality in ICU patients with Acinetobacter baumannii ventilator-associated pneumonia: impact of bacterial cytotoxicity. J Thorac Dis 2018; 10:2608–2617.
Chaari A, Mnif B, Bahloul M, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis 2013; 17:e1225–e1228.
Fang C, Xu L, Li Y, et al. Clinical epidemiology, treatment, and prognostic factors of hospital-acquired pneumonia caused by the extensively drug-resistant Acinetobacter Baumannii . Clin Lab 2023; 69:84–91.
Shu H, Li L, Wang Y, et al. Prediction of the risk of hospital deaths in patients with hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter baumannii infection: a multi-center study. Infect Drug Resist 2020; 13:4147–4154.
Peng C, Zong Z, Fan H. Acinetobacter baumannii isolates associated with community-acquired pneumonia in West China. Clin Microbiol Infect 2012; 18:E491–E493.
Tonnii S, Chua HH. Case series: fulminant community-acquired Acinetobacter pneumonia . Med J Malaysia 2020; 75:186–188.
Bachoumas K, Lebert C, Lacherade JC, Reignier J. Community-acquired Acinetobacter baumannii pneumonia. Med Mal Infect 2015; 45:337–339.
Anstey NM, Currie BJ, Hassell M, et al. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii , with carriage in the throat in at-risk groups. J Clin Microbiol 2002; 40:685–686.
Ong CW, Lye DC, Khoo KL, et al. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. Respirology 2009; 14:1200–1205.
Serota DP, Sexton ME, Kraft CS, Palacio F. Severe community-acquired pneumonia due to Acinetobacter baumannii in North America: case report and review of the literature. Open Forum Infect Dis 2018; 5:ofy044:1-3.
Cisneros JM, Reyes MJ, Pachón J, et al. Bacteremia due to Acinetobacter baumannii : epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026–1032.
Kim SY, Jung JY, Kang YA, et al. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit. J Korean Med Sci 2012; 27:939–947.
Yang S, Sun J, Wu X, Zhang L. Determinants of mortality in patients with nosocomial Acinetobacter baumannii bacteremia in southwest China: a five-year case–control study. Can J Infect Dis Med Microbiol 2018; 2018:3150965–3150973.
Son HJ, Cho EB, Bae M, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Open Forum Infect Dis 2020; 7: ofaa378:1–7.
Mete B, Kurt AF, Urkmez S, et al. The bad bug is back: Acinetobacter baumannii bacteremia outbreak during the COVID-19 pandemic in an intensive care unit. Niger J Clin Pract 2022; 25:702–709.
Min EK, Yim SH, Choi MC, et al. Incidence, mortality, and risk factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation. Clin Transplant 2023; 37:e14956–e14962.
Ljungquist O, Nazarchuk O, Kahlmeter G, et al. Highly multidrug-resistant Gram-negative bacterial infections in war victims in Ukraine, 2022. Lancet Infect Dis 2023; 23:784–786.
Petrosillo N, Petersen E, Antoniak S. Ukraine war and antimicrobial resistance. Lancet Infect Dis 2023; 23:653–654.
Jabbour JF, Sharara SL, Kanj SS. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Curr Opin Infect Dis 2020; 33:146–154.
Qian Z, Zhang S, Li N, et al. Risk factors for and clinical outcomes of polymicrobial Acinetobacter baumannii bloodstream infections. Biomed Res Int 2022; 2022:5122085–5122095.
Russo A, Trecarichi EM, Torti C. The role of Gram-negative bacteria in skin and soft tissue infections. Curr Opin Infect Dis 2022; 35:95–102.
Dong C, Wang J, Chen H, et al. Synergistic therapeutic efficacy of ebselen and silver ions against multidrug-resistant Acinetobacter baumannii -induced urinary tract infections. Metallomics 2020; 12:860–867.
Djordjevic Z, Folic MM, Zivic Z, et al. Nosocomial urinary tract infections caused by Pseudomonas aeruginosa and Acinetobacter species: sensitivity to antibiotics and risk factors. Am J Infect Control 2013; 41:1182–1187.
Sturiale M, Corpina C, Sturiale L. Endocarditis due to Acinetobacter baumannii . Int J Cardiol 2016; 209:161–163.
Olut AI, Erkek E. Early prosthetic valve endocarditis due to Acinetobacter baumannii : a case report and brief review of the literature. Scand J Infect Dis 2005; 37:919–921.
Rizos I, Tsiodras S, Papathanasiou S, et al. Prosthetic valve endocarditis due to Acinetobacter spp: a rare case and literature review. Am J Med Sci 2007; 333:197–199.
Lahmidi I, Charmake D 3rd, Elouafi N, Bazid Z. Acinetobacter baumannii native valve infective endocarditis: a case report. Cureus 2020; 12:11527–11531.
Afeke I, Adu-Amankwaah J, Nyarko M, et al. Acinetobacter baumannii-induced infective endocarditis: new insights into pathophysiology and antibiotic resistance mechanisms. Future Microbiol 2022; 17:1335–1344.
Wroblewska MM, Dijkshoorn L, Marchel H, et al. Outbreak of nosocomial meningitis caused by Acinetobacter baumannii in neurosurgical patients. J Hosp Infect 2004; 57:300–307.
Kelkar R, Gordon SM, Giri N, et al. Epidemic iatrogenic Acinetobacter spp. meningitis following administration of intrathecal methotrexate. J Hosp Infect 1989; 14:233–243.
Krol V, Hamid NS, Cunha BA. Neurosurgically related nosocomial Acinetobacter baumannii meningitis: report of two cases and literature review. J Hosp Infect 2009; 71:176–180.
Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009; 9:245–255.
Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 2010; 14:e572–e579.
Wu X, Wang L, Ye YZ, Yu H. Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: a case report. World J Clin Cases 2019; 7:4342–4348.
Xiao J, Zhang C, Ye S. Acinetobacter baumannii meningitis in children: a case series and literature review. Infection 2019; 47:643–649.
Oliveira PR, Carvalho VC, Saconi ES, et al. Tigecycline versus colistin in the treatment of carbapenem-resistant Acinetobacter baumannii complex osteomyelitis. J Bone Jt Infect 2020; 5:60–66.
Vignesh P, Bhattad S, Shandilya JK, et al. Vertebral osteomyelitis and Acinetobacter spp. paravertebral soft tissue infection in a 4-year-old boy with X-linked chronic granulomatous disease. Pediatr Infect Dis J 2016; 35:1043–1045.
Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 2008; 14:512–514.
Mahajan VM. Postoperative ocular infections: an analysis of laboratory data on 750 cases. Ann Ophthalmol 1984; 16:847–848.
Bert F, Lambert-Zechovsky N. Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15:533–544.
Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii . FEMS Microbiol Lett 2006; 258:72–77.
Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii . Antimicrob Agents Chemother 2015; 59:1680–1689.
Krizova L, Poirel L, Nordmann P, Nemec A. TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii . J Antimicrob Chemother 2013; 68:2786–2791.
Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important Acinetobacter spp.: an update. Future Sci OA 2019; 5: Fso395:1–14.
Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50:2941–2945.
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281.
Centers for Disease Control and Prevencion (CDC). Antimicrobial-resistant phenotype definitions analysis of antimicrobial-resistant organisms in NHSN Upd. Available at: https://wwwcdcgov/nhsn/pdfs/ps-analysis-resources/phenotype_definitionspdf [last updated 01/2022; last accessed 25 July 2023].
Kanafani ZA, Calderwood SB, Hall KK. Acinetobacter infection: treatment and prevention. UpToDate 2023; 1–49.
Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component. Diagn Microbiol Infect Dis 2007; 57:207–215.
Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States. Diagn Microbiol Infect Dis 2009; 65:414–426.
Lasarte-Monterrubio C, Vázquez-Ucha JC, Maneiro M, et al. Activity of imipenem, meropenem, cefepime, and sulbactam in combination with the β-lactamase inhibitor LN-1-255 against Acinetobacter spp. Antibiotics (Basel) 2021; 10:210–223.
Yang Y, Guo Y, Yin D, et al. In vitro activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii : results from China Antimicrobial Surveillance Network (CHINET). Antimicrob Agents Chemother 2020; 65:e01726–e1820.
Pascual A, López-Hernández I, Martínez-Martínez L, Perea EJ. In-vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones. J Antimicrob Chemother 1997; 40:140–142.
Lee K, Lee MA, Lee CH, et al. Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007. Yonsei Med J 2010; 51:901–911.
Seifert H, Blondeau J, Lucaßen K, Utt EA. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes. J Glob Antimicrob Resist 2022; 31:82–89.
Saleh NM, Saad SI, El-Sayed M, et al. Contribution of different mechanisms to aminoglycoside resistance in clinical isolates of Acinetobacter baumannii . Microb Pathog 2023; 182: 106255:1–10.
Jouybari MA, Ahanjan M, Mirzaei B, Goli HR. Role of aminoglycoside-modifying enzymes and 16S rRNA methylase (ArmA) in resistance of Acinetobacter baumannii clinical isolates against aminoglycosides. Rev Soc Bras Med Trop 2021; 54:e5992020–e5992029.
Liu JY, Wang FD, Ho MW, et al. In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan. J Microbiol Immunol Infect 2016; 49:918–923.
Wang JL, Lai CC, Ko WC, Hsueh PR. Geographic patterns of in vitro susceptibilities to tigecycline and colistin among worldwide isolates of Acinetobacter baumannii , Escherichia coli and Klebsiella pneumoniae : data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016 to 2021. Int J Antimicrob Agents 2023; 106930–106937.
Simor AE, Louie L, Louie M. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents. Eur J Clin Microbiol Infect Dis 1994; 13:521–523.
García-Fernández S, Bala Y, Armstrong T, et al. Multicenter evaluation of the new etest gradient diffusion method for piperacillin-tazobactam susceptibility testing of enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii complex. J Clin Microbiol 2020; 58:e01042–e1119.
Pandey A, Kapil A, Sood S, et al. In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii . J Clin Microbiol 1998; 36:3415–3416.
Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004; 48:1586–1592.
Segatore B, Piccirilli A, Cherubini S, et al. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii clinical isolates: a multicentre report from Italy. Antibiotics (Basel) 2022; 11:1136–1146.
Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii -calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother 2022; 66:e0078122–e78129.
Liu PY, Ko WC, Lee WS, et al. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020. J Microbiol Immunol Infect 2022; 55:888–895.
Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary Gram-negative pathogens from New York City hospitals. Microb Drug Resist 2021; 27:190–195.
Trebosc V, Schellhorn B, Schill J, et al. In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms. J Antimicrob Chemother 2020; 75:3552–3562.
Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34:111–120.
European CDC. Antimicrobial resistance surveillance in Europe 2020–2022 data. 2022. Available at: https://wwwecdceuropaeu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022–2020-data [last accessed 25 July 2023].
World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. Geneva. Available at: https://wwwwhoint/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHOpdf [last accessed 25 July 2023].
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections. Clin Infect Dis 2023; ciad428:1–53.
Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:391–400.
Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014; 58:5598–5601.
Sirijatuphat R, Thawornkaew S, Ruangkriengsin D, Thamlikitkul V. Colistin monotherapy versus colistin plus sitafloxacin for therapy of carbapenem-resistant Acinetobacter baumannii infections: a preliminary study. Antibiotics (Basel) 2022; 11:1707–1716.
Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii : a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349–358.
Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141:1214–1222.
Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med 2018; 22:67–77.
Park HJ, Cho JH, Kim HJ, et al. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii : a randomised controlled trial. J Glob Antimicrob Resist 2019; 17:66–71.
Viana GF, Saalfeld SM, Moreira RR, et al. Can ampicillin/sulbactam resistance in Acinetobacter baumannii be predicted accurately by disk diffusion? J Glob Antimicrob Resist 2013; 1:221–223.
Assimakopoulos SF, Karamouzos V, Lefkaditi A, et al. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii : a case series study. Infez Med 2019; 27:11–16.
Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist 2021; 24:136–147.
Jung SY, Lee SH, Lee SY, et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care 2017; 21: 319:1-15.
Fernández-Cuenca F, Tomás M, Caballero-Moyano FJ, et al. Reporting antimicrobial susceptibilities and resistance phenotypes in Acinetobacter spp: a nationwide proficiency study. J Antimicrob Chemother 2018; 73:692–697.
Beganovic M, Daffinee KE, Luther MK, LaPlante KL. Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2021; 65:e01680–e01720.
Lenhard JR, Smith NM, Bulman ZP, et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother 2017; 61:301268–301316.
Abdul-Mutakabbir JC, Yim J, Nguyen L, et al. In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii . Antibiotics (Basel) 2021; 10:880–890.
Rodríguez-Hernández MJ, Cuberos L, Pichardo C, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001; 47:479–482.
Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii . Scand J Infect Dis 2007; 39:38–43.
Qin Y, Zhang J, Wu L, et al. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii . Int J Clin Pharmacol Ther 2018; 56:120–129.
Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 2015; 9:476–485.
Ungthammakhun C, Vasikasin V, Changpradub D. A randomized controlled trial of colistin combined with sulbactam: 9 g per day versus 12 g per day in the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia: an interim analysis. Antibiotics (Basel) 2022; 11:1112–1124.
Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis. J Infect Chemother 2017; 23:278–285.
Chu H, Zhao L, Wang M, et al. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 2013; 17:389–394.
Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001; 21:142–148.
Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425–1430.
Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369–1375.
Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54:32–38.
Lickliter JD, Lawrence K, O’Donnell J, Isaacs R. Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2020; 64:e00071–e20.
Keam SJ. Sulbactam/durlobactam: first approval. Drugs 2023; 83:1245–1252.
Granata G, Taglietti F, Schiavone F, Petrosillo N. Durlobactam in the treatment of multidrug-resistant Acinetobacter baumannii infections: a systematic review. J Clin Med 2022; 11:3258–72.
Gijón Cordero D, Castillo-Polo JA, Ruiz-Garbajosa P, Cantón R. Antibacterial spectrum of cefiderocol. Rev Esp Quimioter 2022; 35: (Suppl 2): 20–27.
Kollef M, Dupont H, Greenberg DE, et al. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence. Int J Antimicrob Agents 2023; 62:106882–106896.
McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother 2021; 65:e0217120.
Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 2017; 36:2319–27.
Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018; 62:e01968–17.
Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 2017; 61:e00093–17.
Ito A, Kohira N, Bouchillon SK, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 2016; 71:670–677.
Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 2018; 62:e01454–17.
Viale P, Sandrock CE, Ramirez P, et al. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care 2023; 13:52–76.
Domingues S, Lima T, Saavedra MJ, Da Silva GJ. An overview of cefiderocol's therapeutic potential and underlying resistance mechanisms. Life (Basel) 2023; 13:1427–1442.
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018; 18:1319–1328.
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226–240.
Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021; 21:213–225.
Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii . Antimicrob Agents Chemother 2022; 66:e0214221–e214232.
Falcone M. Education: an overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’. JAC Antimicrob Resist 2021; 3:i25.
Bassetti M, Vena A, Castaldo N, et al. Clinical evidence supporting cefiderol for serious Acinetobacter baumannii infections. Curr Opin Infect Dis 2022; 35:545–551.
Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69:2305–2309.
Nutman A, Lellouche J, Temkin E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect 2020; 26:1185–1191.
Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid 2023; 2:10–30.
Lesho E, Wortmann G, Moran K, Craft D. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis 2005; 41:758–759.
Jones RN, Sader HS, Fritsche TR, Rhomberg PR. Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis 2006; 42:158.
Esterly JS, Qi C, Malczynski M, Scheetz MH. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. Pharmacotherapy 2010; 30:354–360.
Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis 2014; 59: (Suppl 6): S367–S373.
Sodeifian F, Zangiabadian M, Arabpour E, et al. Tigecycline-containing regimens and multi drug-resistant Acinetobacter baumannii : a systematic review and meta-analysis. Microb Drug Resist 2023; 29:344–359.
Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii , including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015; 59:1802–1805.
Li Y, Cui L, Xue F, et al. Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii . J Glob Antimicrob Resist 2022; 30:56–59.
Scott CJ, Zhu E, Jayakumar RA, et al. Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii . Ann Pharmacother 2022; 56:1299–1307.
Alosaimy S, Morrisette T, Lagnf AM, et al. Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii . Microbiol Spectr 2022; 10:e0047922–e0047929.
Dong D, Zheng Y, Chen Q, et al. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018. Eur J Clin Microbiol Infect Dis 2020; 39:1559–1572.
Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. J Glob Antimicrob Resist 2021; 27:337–351.
Abbey T, Vialichka A, Jurkovic M, et al. Activity of omadacycline alone and in combination against carbapenem-nonsusceptible acinetobacter baumannii with varying minocycline susceptibility. Microbiol Spectr 2022; 10:e0054222–e0054231.
Morrisette T, Alosaimy S, Lagnf AM, et al. Real-world, multicenter case series of patients treated with oral omadacycline for resistant Gram-negative Pathogens. Infect Dis Ther 2022; 11:1715–1723.
Clinicaltrials.gov. Omadacycline. Available at: https://classicclinicaltrialsgov/ct2/results?cond=omadacycline&term=&cntry=&state=&city=&dist = [Accessed 16 August 2023].
Trebosc V, Kemmer C, Lociuro S, et al. Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections. Drug Discov Today 2021; 26:2099–2104.
Lee B, Yan J, Ulhaq A, et al. In vitro activity of rifabutin and rifampin against antibiotic-resistant Acinetobacter baumannii , Escherichia coli , Staphylococcus aureus , Pseudomonas aeruginosa , and Klebsiella pneumoniae . mSphere 2021; 6:e0092021–e0092029.
Cheng J, Yan J, Reyna Z, et al. Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii . Antimicrob Agents Chemother 2021; 65:e02204–e02220.
Mohammadi M, Khayat H, Sayehmiri K, et al. Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii : a systematic review and meta-analysis. Open Microbiol J 2017; 11:63–71.
Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a Murine Thigh-Infection Model. PLoS One 2016; 11:e0157757–e0157768.
Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2019; 63:e01110–e01118.
Nwabor OF, Terbtothakun P, Voravuthikunchai SP, Chusri S. Evaluation of the synergistic antibacterial effects of fosfomycin in combination with selected antibiotics against carbapenem-resistant Acinetobacter baumannii . Pharmaceuticals (Basel) 2021; 14:185–201.
Sharma A, Sharma R, Bhattacharyya T, et al. Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF. J Antimicrob Chemother 2017; 72:68–74.
Gil-Marqués ML, Moreno-Martínez P, Costas C, et al. Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii . J Antimicrob Chemother 2018; 73:2960–2968.
Leite GC, Perdigão-Neto LV, Ruedas Martins RC, et al. Genetic factors involved in fosfomycin resistance of multidrug-resistant Acinetobacter baumannii . Infect Genet Evol 2021; 93:104943–104947.
Santimaleeworagun W, Wongpoowarak P, Chayakul P, et al. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011; 42:890–900.
Leelasupasri S, Santimaleeworagun W, Jitwasinkul T. Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii . J Pathog 2018; 2018:3893492–3893496.
Singkham-In U, Chatsuwan T. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis 2018; 91:169–174.
Mohd Sazlly Lim S, Heffernan AJ, Roberts JA, Sime FB. Pharmacodynamic analysis of meropenem and fosfomycin combination against carbapenem-resistant Acinetobacter baumannii in patients with normal renal clearance: can it be a treatment option? Microb Drug Resist 2021; 27:546–552.
Zhang Y, Chen F, Sun E, et al. In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii . Exp Ther Med 2013; 5:1737–1739.
Russo A, Bassetti M, Bellelli V, et al. Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii : a prospective, observational study. Infect Dis Ther 2021; 10:187–200.
Assimakopoulos SF, Karamouzos V, Eleftheriotis G, et al. Efficacy of fosfomycin-containing regimens for treatment of bacteremia due to pan-drug resistant Acinetobacter baumannii in critically ill patients: a case series study. Pathogens 2023; 12:286–292.
Park S, Lee KM, Yoo YS, et al. Alterations of gyrA, gyrB, and parC and activity of efflux pump in fluoroquinolone-resistant Acinetobacter baumannii . Osong Public Health Res Perspect 2011; 2:164–170.
Saroj SD, Clemmer KM, Bonomo RA, Rather PN. Novel mechanism for fluoroquinolone resistance in Acinetobacter baumannii . Antimicrob Agents Chemother 2012; 56:4955–4957.
Higgins PG, Zander E, Seifert H. Identification of a novel insertion sequence element associated with carbapenem resistance and the development of fluoroquinolone resistance in Acinetobacter radioresistens . J Antimicrob Chemother 2013; 68:720–722.
Roy S, Chatterjee S, Bhattacharjee A, et al. Overexpression of efflux pumps, mutations in the pumps’ regulators, chromosomal mutations, and AAC(6’)-Ib-cr are associated with fluoroquinolone resistance in diverse sequence types of neonatal septicaemic Acinetobacter baumannii : a 7-year single center study. Front Microbiol 2021; 12:602724–602738.
Venkataramana GP, Lalitha AKV, Mariappan S, Sekar U. Plasmid-mediated fluoroquinolone resistance in Pseudomonas aeruginosa and Acinetobacter baumannii . J Lab Physicians 2022; 14:271–277.
Drago L, De Vecchi E, Nicola L, et al. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy 2004; 50:202–210.
Madadi-Goli N, Moniri R, Bagheri-Josheghani S, Dasteh-Goli N. Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii . Iran J Microbiol 2017; 9:19–25.
Wei W, Yang H, Hu L, et al. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii : in vitro and in a Galleria mellonella model. J Microbiol Immunol Infect 2017; 50:821–830.
Ermertcan S, Hoşgör M, Tünger O, Coşar G. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections. Scand J Infect Dis 2001; 33:818–821.
Joly-Guillou ML, Wolff M, Farinotti R, et al. In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother 2000; 46:827–830.
Mosaed R, Haghighi M, Kouchak M, et al. Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter . Iran J Pharm Res 2018; 17:206–213.
Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus - baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55:49–57.
Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med 2016; 11:21–26.
Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii : clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67:1607–1615.
Velkov T, Roberts KD, Li J. Rediscovering the octapeptins. Nat Prod Rep 2017; 34:295–309.
Nang SC, Azad MAK, Velkov T, et al. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev 2021; 73:679–728.
Kim M, Park J, Park W. Genomic and phenotypic analyses of multidrug-resistant Acinetobacter baumannii NCCP 16007 isolated from a patient with a urinary tract infection. Virulence 2021; 12:150–164.
Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii : pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist 2018; 11:1249–1260.
Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Clin Infect Dis 1999; 28:1008–1011.
Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111–1118.
Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670–680.
Dickstein Y, Lellouche J, Ben Dalak Amar M, et al. Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis 2019; 69:769–776.
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27–R39.
Durante-Mangoni E, Andini R, Signoriello S, et al. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections. Clin Microbiol Infect 2016; 22:984–989.
Kang AD, Smith KP, Berg AH, et al. Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model. Antimicrob Agents Chemother 2018; 62:e02585–2617.
Becker K, Aranzana-Climent V, Cao S, et al. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clin Microbiol Infect 2021; 27:1315–1321.
Galani I, Papoutsaki V, Karaiskos I, et al. In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020–2021: a multicenter study. Eur J Clin Microbiol Infect Dis 2023; 42:843–852.
Juhas M, Widlake E, Teo J, et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii . J Antimicrob Chemother 2019; 74:944–952.
Kang AD, Smith KP, Eliopoulos GM, et al. In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa . Diagn Microbiol Infect Dis 2017; 88:188–191.
Tu Q, Pu M, Li Y, et al. Acinetobacter baumannii phages: past, present and future. Viruses 2023; 15:673–699.
Zhang Y, Lin Y, Galgano S, et al. Recent progress in phage therapy to modulate multidrug-resistant Acinetobacter baumannii , including in human and poultry. Antibiotics (Basel) 2022; 11:1406–1421.
Zagaliotis P, Michalik-Provasek J, Gill JJ, Walsh TJ. Therapeutic bacteriophages for Gram-negative bacterial infections in animals and humans. Pathog Immun 2022; 7:1–45.
Rai S, Kumar A. Bacteriophage therapeutics to confront multidrug-resistant Acinetobacter baumannii - a global health menace. Environ Microbiol Rep 2022; 14:347–364.
Lood R, Winer BY, Pelzek AJ, et al. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 2015; 59:1983–1991.
Peters DL, Davis CM, Harris G, et al. Characterization of virulent T4-like Acinetobacter baumannii bacteriophages DLP1 and DLP2. Viruses 2023; 15:739–763.
Mardiana M, Teh SH, Tsai YC, et al. Characterization of a novel and active temperate phage vB_AbaM_ABMM1 with antibacterial activity against Acinetobacter baumannii infection. Sci Rep 2023; 13:11347–11359.
Luo J, Xie L, Yang M, et al. Synergistic antibacterial effect of phage pB3074 in combination with antibiotics targeting cell wall against multidrug-resistant Acinetobacter baumannii in vitro and ex vivo. Microbiol Spectr 2023; e0034123–e0034133.
Li Y, Xiao S, Huang G. Acinetobacter baumannii bacteriophage: progress in isolation, genome sequencing, preclinical research, and clinical application. Curr Microbiol 2023; 80:199–210.
Huang L, Huang S, Jiang L, et al. Characterisation and sequencing of the novel phage Abp95, which is effective against multi-genotypes of carbapenem-resistant Acinetobacter baumannii . Sci Rep 2023; 13:188–198.
Bagińska N, Harhala MA, Cieślik M, et al. Biological properties of 12 newly isolated Acinetobacter baumannii -specific bacteriophages. Viruses 2023; 15:231–250.
Zhu Y, Han K, Chen L, et al. Biological characterization and genomic analysis of Acinetobacter baumannii phage BUCT628. Arch Virol 2022; 167:1471–1474.
Sisakhtpour B, Mirzaei A, Karbasizadeh V, et al. The characteristic and potential therapeutic effect of isolated multidrug-resistant Acinetobacter baumannii lytic phage. Ann Clin Microbiol Antimicrob 2022; 21:1–11.
Kolsi A, Haukka K, Dougnon V, et al. Isolation and characterization of three novel Acinetobacter baumannii phages from Beninese hospital wastewater. Arch Virol 2023; 168:228–234.
Malik DJ, Sokolov IJ, Vinner GK, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci 2017; 249:100–133.
Wintachai P, Phaonakrop N, Roytrakul S, et al. Enhanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii . Sci Rep 2022; 12:2633–2651.
Wintachai P, Surachat K, Singkhamanan K. Isolation and characterization of a novel autographiviridae phage and its combined effect with tigecycline in controlling multidrug-resistant Acinetobacter baumannii -associated skin and soft tissue infections. Viruses 2022; 14:194–218.
Nir-Paz R, Gelman D, Khouri A, et al. Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis 2019; 69:2015–2018.
Oliveira H, Costa AR, Ferreira A, et al. Functional analysis and antivirulence properties of a new depolymerase from a myovirus that infects Acinetobacter baumannii Capsule K45. J Virol 2019; 93:e01163–e01178.
Euler CW, Raz A, Hernandez A, et al. PlyKp104, a novel phage lysin for the treatment of Klebsiella pneumoniae , Pseudomonas aeruginosa , and other Gram-negative ESKAPE pathogens. Antimicrob Agents Chemother 2023; 67:e0151922–e0151936.
Luo J, Xie L, Liu M, et al. Bactericidal synergism between phage YC#06 and antibiotics: a combination strategy to target multidrug-resistant Acinetobacter baumannii in vitro and in vivo. Microbiol Spectr 2022; 10:e0009622–e0009632.
Neto S, Vieira A, Oliveira H, Espiña B. Assessing Acinetobacter baumannii virulence and treatment with a bacteriophage using zebrafish embryos. FASEB j 2023; 37:e23013–e23022.
Gordillo Altamirano FL, Kostoulias X, Subedi D, et al. Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine 2022; 80:104045–104059.
Wienhold SM, Brack MC, Nouailles G, et al. Preclinical assessment of bacteriophage therapy against experimental Acinetobacter baumannii lung infection. Viruses 2021; 14:33–50.
Taati Moghadam M, Khoshbayan A, Chegini Z, et al. Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials. Drug Des Devel Ther 2020; 14:1867–1883.
Erol HB, Kaskatepe B, Yildiz S, Altanlar N. The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms. J Microbiol Methods 2023; 210:106752–106758.
Patel SR, Pratap CB, Nath G. Evaluation of bacteriophage cocktail on septicaemia caused by colistin-resistant Acinetobacter baumannii in immunocompromised mice model. Indian J Med Res 2021; 154:141–149.
Tan Y, Su J, Fu M, et al. Recent advances in phage-based therapeutics for multi-drug resistant Acinetobacter baumannii . Bioengineering (Basel) 2022; 10:35–45.
Düzgüneş N, Sessevmez M, Yildirim M. Bacteriophage therapy of bacterial infections: the rediscovered frontier. Pharmaceuticals (Basel) 2021; 14:34–49.
Rao S, Betancourt-Garcia M, Kare-Opaneye YO, et al. Critically Ill patient with multidrug-resistant Acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy. Antimicrob Agents Chemother 2022; 66:e0082421–e82426.
Liu M, Hernandez-Morales A, Clark J, et al. Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a patient undergoing phage therapy. Nat Commun 2022; 13:3776–3789.
Wu N, Dai J, Guo M, et al. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients. Emerg Microbes Infect 2021; 10:612–618.
Tan X, Chen H, Zhang M, et al. Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Front Cell Infect Microbiol 2021; 11:631585–631591.
Yan W, Banerjee P, Liu Y, et al. Development of thermosensitive hydrogel wound dressing containing Acinetobacter baumannii phage against wound infections. Int J Pharm 2021; 602:120508–120517.
Satta G, O’Callagharn C, Clokie MRJ, Di Luca M. Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections. Curr Opin Pulm Med 2022; 28:225–231.
Choi HK, Kim YK, Kim HY, Uh Y. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii . Yonsei Med J 2014; 55:118–125.
Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645–2649.
Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. Chest 2017; 151:1239–1246.
Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis 2020; 20:330–340.
Zhang X, Cui X, Jiang M, et al. Nebulized colistin as the adjunctive treatment for ventilator-associated pneumonia: a systematic review and meta-analysis. J Crit Care 2023; 77:154315–154322.
Hakamifard A, Torfeh Esfahani AA, Homayouni A, et al. Comparing inhaled colistin with inhaled fosfomycin/tobramycin as an adjunctive treatment for ventilator-associated pneumonia: an open-label randomized controlled trial. Clin Respir J 2023; 17:295–302.
Qin JP, Huang HB, Zhou H, et al. Amikacin nebulization for the adjunctive therapy of Gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 2021; 11:6969–6977.